European Archives - Page 27 of 1164 - European Medical Journal

One-Third of Patients with Myeloma May Achieve Long-Term Survival

A new analysis of early total therapy clinical trials has revealed that up to one-third of patients with newly diagnosed multiple myeloma may achieve long-term survival.

ERA 2025: Immune Profiling of Checkpoint Inhibitor-Induced Nephritis Reveals Distinct Subtypes with Prognostic Value

Presented at ERA 2025, this multicentre study identifies three immune subtypes of checkpoint inhibitor–induced nephritis, linking them to clinical outcomes and treatment responses.

Nasal Test Enhances Allergy Diagnosis Accuracy

This study investigates the role of the intranasal Schirmer test as a supportive or alternative tool to anterior rhinomanometry for allergic rhinitis.

Progesterone-Only Pill Linked to Higher Asthma Risk in Young Women

Progestogen-only contraceptives may raise the risk of asthma attacks in younger women and those with eosinophilic asthma, according to a new population-based cohort study.

National Study Reveals Gaps in Paediatric Hepatitis C Treatment

These figures indicate a substantial drop-off following diagnosis, undermining efforts to eliminate HCV in paediatric populations.

Lower Transfusion Thresholds May Be Safe for Children Post-Transplant

A new UK clinical trial has found that children undergoing stem cell transplants may safely receive fewer blood transfusions.

Trial Shows No Added Benefit From Antibiotics Before Appendectomy

A large randomized clinical trial suggests that adults with uncomplicated appendicitis can safely wait for surgery without receiving antibiotics.

Social media key to Gen Z pharma hires, says ABPI

According to new research from the ABPI, pharma companies need to modernise their outreach strategies.

Is Short-Course Tuberculosis Treatment Ready for Practice?

Participants were randomised to receive either the WHO-recommended 24-week standard regimen or one of four novel 8-week regimens.

ERA 2025: Higher-Dose Canagliflozin Yields Greater Cardiovascular Protection in High-Risk Patients

A post-hoc analysis of the CANVAS trial reveals a dose-dependent cardiovascular benefit with canagliflozin in type 2 diabetes, while kidney protection appears consistent across doses.